Harmony Biosciences stock holds near USD 41.86

Harmony Biosciences Holdings, Inc. (US41319J1088) stock held near USD 41.86 in the latest Yahoo Finance snapshot, with a market capitalization of USD 2.459 billion and volume of 284,884 shares on September 4, 2026.

The same snapshot puts the shares between a day low of USD 41.36 and a previous close of USD 41.86, giving investors a clean reference point ahead of the next session.

Latest quarter still carries weight

Yahoo Finance also shows Q2 FY26 revenue of USD 261.28 million and earnings of USD 75.43 million, with a profit margin of 28.87 percent. Those figures frame Harmony as a profitable specialty pharma name rather than a simple momentum trade.

For comparison, the latest reported quarter also came with earnings per share of USD 3.09 on a trailing basis, which helps explain why the market is paying attention to cash generation and margin quality.

Margin and volume matter

Volume of 284,884 shares was below the average volume of 813,446, so the market move was not driven by a heavy-turnover session. That makes the USD 2.459 billion market cap and the USD 41.36 to USD 41.86 session band the key trading signals from September 4, 2026.

The current setup is simple: revenue, earnings and margin all point to a company that still has operating strength, while the stock itself remains close to its previous close.

Wakix stays central

Harmony Biosciences' core product is Wakix, the narcolepsy treatment that remains the companys main commercial driver. The latest quarter figures are important because they show how much the market is still anchoring on that single product franchise.

Stock level after the snapshot

Harmony Biosciences stock traded at USD 41.86 on September 4, 2026, with a market capitalization of USD 2.459 billion. The session range of USD 41.36 to USD 41.86 shows the shares finished right at the previous close.